Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents

Rajangad S. Gurtatta; Sydney E. Whalen; Charles E. Ray Jr.

doi:10.1055/s-0043-1778660

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2024; 41(01): 084-091
DOI: 10.1055/s-0043-1778660

Clinical Corner

Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents

Rajangad S. Gurtatta

¹University of Illinois College of Medicine, Chicago, Illinois

,

Sydney E. Whalen

¹University of Illinois College of Medicine, Chicago, Illinois

,

Charles E. Ray Jr.

²Department of Radiology, University of Illinois College of Medicine, Chicago, Illinois

References
1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. [published correction appears in CA Cancer J Clin 2020;70(4):313] CA Cancer J Clin 2018; 68 (06) 394-424
2 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
3 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol 2015; 7 (03) 406-424
4 Di Muzio B, Bell D, Malik A. et al. ECOG performance status. Am J Clin Oncol 1982; 5: 649-655
5 Tsoris A, Marlar CA. Use of the Child Pugh Score in Liver Disease. [Updated March 13, 2023]. In: StatPearls [Internet]. Treasure Island, FL:: StatPearls Publishing;; 2023
6 Trivedi HD. The evolution of the MELD score and its implications in liver transplant allocation: a beginner's guide for trainees. ACG Case Rep J 2022; 9 (05) e00763
7 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
8 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY Study. Hepatology 2021; 74 (05) 2342-2352
9 Hasegawa K, Kokudo N, Makuuchi M. et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. [published correction appears in J Hepatol 2013;59(3):641] J Hepatol 2013; 58 (04) 724-729
10 Tabrizian P, Holzner ML, Mehta N. et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg 2022; 157 (09) 779-788
11 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
12 Yao FY, Kerlan Jr RK, Hirose R. et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48 (03) 819-827
13 Graziadei IW, Sandmueller H, Waldenberger P. et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9 (06) 557-563
14 Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol 2011; 2011: 974514
15 Salem R, Gordon AC, Mouli S. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
16 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 2021; 75 (04) 960-974
17 Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol 2019; 10 (December): 2965
18 Pisibon C, Ouertani A, Bertolotto C, Ballotti R, Cheli Y. Immune checkpoints in cancers: from signaling to the clinic. Cancers (Basel) 2021; 13 (18) 4573
19 Saad P, Kasi A. Ipilimumab. [Updated 2023 Apr 10]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing;; 2023. . Accessed December 26, 2023 at: https://www.ncbi.nlm.nih.gov/books/NBK557795/
20 Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits 2015; 8 (Spec Feature): 180-183
21 He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res 2020; 30 (08) 660-669
22 Abou-Alfa GK, George L, Masatoshi K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1 (08) 2100070
23 IMFINZI (Durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. Accessed August 8, 2023 at: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9496217c-08b3-432b-ab4f-538d795820bd/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf Published June 2023
24 IMJUDO (Tremelimumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. Accessed August 8, 2023 at: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0102c6fd-de8a-4b43-afa3-2a2c2115d472/0102c6fd-de8a-4b43-afa3-2a2c2115d472_viewable_rendition__v.pdf . Published June, 2023
25 TECENTRIQ (Atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc. Accessed August 8, 2023 at: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf . Published May, 2023
26 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
27 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307 (5706) 58-62
28 Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: practical considerations in routine clinical practice. World J Hepatol 2021; 13 (09) 1132-1142
29 Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. In: Madame Curie Bioscience Database [Internet]. Austin, TX: Landes Bioscience; 2000-2013
30 AVASTIN (Bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc. Accessed August 8, 2023 at: https://www.gene.com/download/pdf/avastin_prescribing.pdf . Published September, 2022
31 Zhu AX, Kang Y-K, Yen C-J. et al; REACH-2 Study Investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (02) 282-296
32 Yasui Y, Kurosaki M, Tsuchiya K. et al; Japanese Red Cross Liver Study Group. Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study. Cancers (Basel) 2022; 14 (12) 2975
33 CYRAMZA (Ramucirumab) [package insert]. Indianapolis, IN: Eli Lilly and Company. Accessed August 8, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf . Published May, 2020
34 Sangwan V, Park M. Receptor tyrosine kinases: role in cancer progression. Curr Oncol 2006; 13 (05) 191-193
35 HERCEPTIN (Trastuzumab) [package insert]. South San Francisco, CA: Genentech Inc. Accessed August 8, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf . Published October, 2010
36 Kane RC, Farrell AT, Saber H. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12 (24) 7271-7278
37 Forner A, Reig M, Bruix J. Hepatocellular carcinoma, The Lancet, Volume 391, Issue 10127,. 2018 :1301–1314, ISSN 0140–6736. Accessed August 8, 2023 at: https://doi.org/10.1016/S0140-6736(18)30010-2
38 NEXAVAR (Sorafenib) [package insert]. Whippany, NJ: Bayer Healthcare Pharmaceuticals Inc. Accessed August 8, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf . Published December, 2018
39 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391 (10126) 1163-1173
40 Padda IS, Parmar M. Lenvatinib. [Updated 2023 Jan 17]. In: StatPearls [Internet]. Treasure Island, FL:: StatPearls Publishing;; 2023
41 LENVIMA (Lenvatinib) [package insert]. Nutley, NJ: Eisai Inc. Accessed August 8, 2023 at: https://www.lenvima.com/-/media/Project/EISAI/Lenvima/PDF/prescribing-information.pdf . Published November, 2022
42 Bruix J, Qin S, Merle P. et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10064): 56-66
43 STIVARGA (Regorafenib) [package insert]. Whippany, NJ: Bayer Healthcare Pharmaceuticals Inc. Accessed August 8, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203085s007lbl.pdf . Published April, 2017
44 Abou-Alfa GK, Meyer T, Cheng A-L. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379 (01) 54-63
45 CABOMETYX (Cabozantinib) [package insert]. Alameda, CA: Exelixis Inc. Accessed August 8, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s010lbl.pdf . Published January, 2021
46 Kudo M. Atezolizumab plus bevacizumab followed by curative conversion (ABC Conversion) in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma. Liver Cancer 2022; 11 (05) 399-406
47 Kudo M, Ueshima K, Ikeda M. et al; TACTICS Study Group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69 (08) 1492-1501
48 Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep 2014; 41 (10) 6575-6582
49 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. [published correction appears in Lancet Gastroenterol Hepatol 2017;2(9):e6] Lancet Gastroenterol Hepatol 2017; 2 (08) 565-575
50 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016; 64 (05) 1090-1098
51 Kudo M, Imanaka K, Chida N. et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47 (14) 2117-2127
52 Kudo M, Ueshima K, Chan S. et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study. Cancers (Basel) 2019; 11 (08) 1084
53 Kudo M, Han KH, Ye SL. et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020; 9 (03) 245-260
54 Kudo M, Kawamura Y, Hasegawa K. et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 2021; 10 (03) 181-223
55 Llovet JM, Villanueva A, Marrero JA. et al; AASLD Panel of Experts on Trial Design in HCC. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology 2021; 73 (Suppl. 01) 158-191
56 Britten CD, Gomes AS, Wainberg ZA. et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer 2012; 12: 16
57 Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019; 19 (01) 795
58 Ricke J, Klümpen HJ, Amthauer H. et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71 (06) 1164-1174
59 Park MK, Yu SJ. Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. J Liver Cancer 2022; 22 (01) 69-74
60 Wang F, Numata K, Komiyama S. et al. Combination therapy with lenvatinib and radiofrequency ablation for patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh Class A liver function: a pilot study. Front Oncol 2022; 12: 843680
61 Atezolizumab and Bevacizumab in Combination with TACE for the Treatment of BCLC B HCC. . ClinicalTrials.gov ID: NCT05776875. Updated April 7, 2023 . Accessed August 8, 2023 at: https://clinicaltrials.gov/study/NCT05776875
62 Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND). . ClinicalTrials.gov ID: NCT04224636. Updated October 26, 2020 . Accessed August 8, 2023 at: https://classic.clinicaltrials.gov/ct2/show/NCT04224636
63 Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. . ClinicalTrials.gov ID: NCT05185505. Updated February 1, 2023 . Accessed August 8, 2023 at: https://classic.clinicaltrials.gov/ct2/show/NCT05185505